Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00102115Phase 1Terminated

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

Role: lead

NCT00375544Phase 1Completed

Study to Evaluate the Safety and Efficacy of a Low Level Light Device in Patients With Knee Osteoarthritis

Role: lead

NCT00083785Phase 2Completed

Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases

Role: lead

NCT00068068Phase 2Completed

Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases

Role: lead

NCT00028405Phase 1Completed

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

Role: lead

All 5 trials loaded